Antinuclear antibodies and response to IFNbeta-1a therapy in relapsing-remitting multiple sclerosis.

  • Ciccarelli O
  • Bagnato F
  • Mainero C
 et al. 
  • 4


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


We determined whether positive ANA was related to response to rIFNss-1a in 62 relapsing-remitting MS patients. According to the presence of antinuclear antibodies (ANA) at baseline and during the first 6 months of treatment, patients were sorted in different groups. The clinical and MRI outcome during short-term (6 months) and long-term (24 months) treatment period was not statistically different between the groups. Therefore, the response to IFNbeta-1a seems not to be influenced by ANA occurrence either before or during treatment. When the analysis was extended to other autoantibodies (i. e. antithyroid, anticardiolipin) similar results were obtained.

Author-supplied keywords

  • Adjuvants, Immunologic
  • Adjuvants, Immunologic: therapeutic use
  • Adolescent
  • Adult
  • Antibodies, Antinuclear
  • Antibodies, Antinuclear: analysis
  • Female
  • Follow-Up Studies
  • Humans
  • Interferon-beta
  • Interferon-beta: therapeutic use
  • Magnetic Resonance Imaging
  • Male
  • Multiple Sclerosis, Relapsing-Remitting
  • Multiple Sclerosis, Relapsing-Remitting: diagnosis
  • Multiple Sclerosis, Relapsing-Remitting: drug ther
  • Multiple Sclerosis, Relapsing-Remitting: immunolog
  • Time Factors
  • Treatment Outcome

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • O Ciccarelli

  • F Bagnato

  • C Mainero

  • M Salvetti

  • a Paolillo

  • C Gasperini

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free